Literature DB >> 11748436

99m Tc-HMPAO labelled leukocyte scintigraphy in patients with rheumatoid arthritis: a comparison with disease activity.

J Gaál1, A Mézes, B Síró, J Varga, L Galuska, G Jánoky, I Garai, L Bajnok, P Surányi.   

Abstract

The aim of this study was to test the applicability of 99mTc-hexamethylpropylene amine oxime (99mTc-HMPAO) labelled leukocyte joint scintigraphy in the assessment of disease activity in 21 patients with rheumatoid arthritis, and to compare leukocyte scintigraphy with the Disease Activity Score (DAS), a validated activity index developed by the European League Against Rheumatism (EULAR). Twenty-one patients with rheumatoid arthritis were investigated by using 99mTc-HMPAO labelled leukocyte joint scintigraphy. The clinical and laboratory data were recorded, and the DAS was calculated and compared with the scintigraphic results in each case. A relatively high DAS score (4.71+/-1.07) was found in the majority of patients. The degree of accumulation of 99mTc-HMPAO leukocytes showed no correlation with a patient's age, gender, duration of disease, use of disease modifying anti-rheumatic drugs (DMARDs), visual analogue scale (VAS), Richie index, DAS, or any laboratory parameters. In contrast, a significant correlation was found between the global regional accumulation of the labelled leukocytes of the hands and feet, and the swollen-joint count. It is concluded that radiolabelled leukocyte scintigraphy could become one of the promising methods in the assessment of disease activity in patients with rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11748436     DOI: 10.1097/00006231-200201000-00007

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  7 in total

1.  In vivo magnetic resonance imaging and optical imaging comparison of viable and nonviable mesenchymal stem cells with a bifunctional label.

Authors:  Elizabeth Jane Sutton; Tobias D Henning; Sophie Boddington; Stavros Demos; Christian Krug; Reinhardt Meier; John Kornak; Shoujun Zhao; Rick Baehner; Sheida Sharifi; Heike Daldrup-Link
Journal:  Mol Imaging       Date:  2010-10       Impact factor: 4.488

Review 2.  [Molecular imaging: future uses in arthritides].

Authors:  M H Brem; P M Schlechtweg; J Mackenzie; C S Winalski; P Lang
Journal:  Radiologe       Date:  2006-05       Impact factor: 0.635

Review 3.  Evolving role of FDG PET imaging in assessing joint disorders: a systematic review.

Authors:  Kathleen Carey; Babak Saboury; Sandip Basu; Alex Brothers; Alexis Ogdie; Tom Werner; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-14       Impact factor: 9.236

4.  Current imaging strategies in rheumatoid arthritis.

Authors:  Merissa N Zeman; Peter Jh Scott
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-03-28

Review 5.  Rheumatoid arthritis: Nuclear Medicine state-of-the-art imaging.

Authors:  Paulo Henrique Rosado-de-Castro; Sergio Augusto Lopes de Souza; Dângelo Alexandre; Lea Mirian Barbosa da Fonseca; Bianca Gutfilen
Journal:  World J Orthop       Date:  2014-07-18

Review 6.  Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis.

Authors:  James M Mountz; Abass Alavi; John D Mountz
Journal:  Nat Rev Rheumatol       Date:  2012-09-25       Impact factor: 20.543

7.  Alarmin S100A8/S100A9 as a biomarker for molecular imaging of local inflammatory activity.

Authors:  Thomas Vogl; Michel Eisenblätter; Tom Völler; Stefanie Zenker; Sven Hermann; Peter van Lent; Andreas Faust; Christiane Geyer; Beatrix Petersen; Kirsten Roebrock; Michael Schäfers; Christoph Bremer; Johannes Roth
Journal:  Nat Commun       Date:  2014-08-06       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.